Clinical Trials Browser

Bile Duct Neoplasms × Cisplatin × 1 year × Clear all

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

757 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2 Recruiting

33 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT02375880 2025-08-03

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Phase 1 Completed

51 enrolled

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Not yet recruiting

38 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05712356 2025-06-06

BOLSTER

Phase 2 Active not recruiting

67 enrolled

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

Clinical Trials

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

KEYNOTE-966

KEYNOTE-966

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

SAIB

BOLSTER